Nxera Pharma (4565) Jefferies Global Healthcare Conference 2026 summary

Pipeline progress and strategic focus

• Significant progress in in-house obesity, chronic weight management, and rare endocrine disease programs, with a shift from first-in-class to best-in-class targets, focusing on oral small molecules for GLP-1, amylin, and GIP.

• Proprietary NxWave platform enables efficient hit-finding and structural biology, delivering large potency gains and novel chemical positions, especially for GLP-1 and amylin.

• Expectation of pharmaceutical development candidates emerging from the platform within the next year.

• GLP-1 and amylin small molecule programs are the most advanced and differentiated in the obesity pipeline.

Out-licensing and clinical asset updates

• Active discussions underway to out-license phase II-ready EP4 agonist (for IBD) and GPR52 agonist (for schizophrenia), both with completed phase I studies and clean safety profiles.

• EP4 agonist (NXE'744) confirmed gut-restricted, with target engagement and early UC patient data; GPR52 agonist previously partnered, now returned and phase II-ready.

• Both assets expected to find new partners in the second half of the year, with potential for monotherapy or combination therapy.

Oncology and EP4 antagonist development

• Encouraged by competitor data on EP4 antagonists in gastric cancer, supporting the mechanism of action and de-risking the approach.

• In-house EP4 antagonist differentiated by compound profile, broader phase II trial across four cancer types, and flexibility for combination with various checkpoint inhibitors.

• Phase II data readout expected mid-next year, with ongoing partnership with Cancer Research UK for clinical execution.